D Sanford1, R Kyle2, A Lazo-Langner3, A Xenocostas4, I Chin-Yee4, K Howson-Jan4, C Hsia4. 1. Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON. ; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON. 2. Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON. 3. Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON. ; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON. 4. Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON.
Abstract
BACKGROUND: We used an interview-assisted survey of patients with chronic myeloid leukemia (cml) at a single tertiary care centre to explore patient reactions to and preferences for, and the risk-acceptability of, stopping tyrosine kinase inhibitor (tki) treatment. METHODS: The study included patients with confirmed cml currently being treated with a tki. The survey was conducted by structured interview using a standard form. Patient preferences were explored in a case-based scenario using 0%-100% visual analog scales and 5-point Likert scales. Data were analyzed using proportions for dichotomous variables and medians and interquartile ranges for continuous variables. RESULTS: Of 63 patients approached, 56 completed the survey. Participant responses suggest that the idea of stopping tki use is appealing to many patients if there is a chance of long-term stable disease and a high probability of response upon restarting a tki. Participants were more likely to stop their tki as the risk of relapse decreased. Participants reported loss of disease control and failure of disease to respond to treatment as important concerns if they chose to stop their tki. CONCLUSIONS: Given the current 60% estimated rate of relapse after discontinuation of tki therapy, most patients with cml chose to continue with tki. However, at the lower relapse rates reported with second-generation tkis, participants were more undecided, demonstrating a basic understanding of risk. Contrary to our hypothesis, neither compliance nor occurrence of side effects significantly affected patient willingness to stop their tki.
BACKGROUND: We used an interview-assisted survey of patients with chronic myeloid leukemia (cml) at a single tertiary care centre to explore patient reactions to and preferences for, and the risk-acceptability of, stopping tyrosine kinase inhibitor (tki) treatment. METHODS: The study included patients with confirmed cml currently being treated with a tki. The survey was conducted by structured interview using a standard form. Patient preferences were explored in a case-based scenario using 0%-100% visual analog scales and 5-point Likert scales. Data were analyzed using proportions for dichotomous variables and medians and interquartile ranges for continuous variables. RESULTS: Of 63 patients approached, 56 completed the survey. Participant responses suggest that the idea of stopping tki use is appealing to many patients if there is a chance of long-term stable disease and a high probability of response upon restarting a tki. Participants were more likely to stop their tki as the risk of relapse decreased. Participants reported loss of disease control and failure of disease to respond to treatment as important concerns if they chose to stop their tki. CONCLUSIONS: Given the current 60% estimated rate of relapse after discontinuation of tki therapy, most patients with cml chose to continue with tki. However, at the lower relapse rates reported with second-generation tkis, participants were more undecided, demonstrating a basic understanding of risk. Contrary to our hypothesis, neither compliance nor occurrence of side effects significantly affected patient willingness to stop their tki.
Authors: Hagop M Kantarjian; Neil P Shah; Jorge E Cortes; Michele Baccarani; Mohan B Agarwal; María Soledad Undurraga; Jianxiang Wang; Juan Julio Kassack Ipiña; Dong-Wook Kim; Michinori Ogura; Carolina Pavlovsky; Christian Junghanss; Jorge H Milone; Franck E Nicolini; Tadeusz Robak; Jan Van Droogenbroeck; Edo Vellenga; M Brigid Bradley-Garelik; Chao Zhu; Andreas Hochhaus Journal: Blood Date: 2011-12-09 Impact factor: 22.113
Authors: D M Ross; S Branford; J F Seymour; A P Schwarer; C Arthur; P A Bartley; C Slader; C Field; P Dang; R J Filshie; A K Mills; A P Grigg; J V Melo; T P Hughes Journal: Leukemia Date: 2010-09-02 Impact factor: 11.528
Authors: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Jaein Seo; B Douglas Smith; Elihu Estey; Ernest Voyard; Bernadette O' Donoghue; John F P Bridges Journal: Curr Med Res Opin Date: 2018-04-27 Impact factor: 2.580
Authors: Giora Sharf; Celia Marin; Jennifer A Bradley; Zack Pemberton-Whiteley; Felice Bombaci; Rita I O Christensen; Bahija Gouimi; Nigel B Deekes; Mina Daban; Jan Geissler Journal: Leukemia Date: 2020-05-26 Impact factor: 11.528